Micropolis Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 30-07-2024
- Paid Up Capital ₹ 0.10 M
as on 30-07-2024
- Company Age 4 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 14.22 M
as on 30-07-2024
- Revenue 63.47%
(FY 2023)
- Profit 80.58%
(FY 2023)
- Ebitda 168.13%
(FY 2023)
- Net Worth 167.57%
(FY 2023)
- Total Assets 49.04%
(FY 2023)
About Micropolis Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.42 Cr.
Jatinder Sharda, Mandeepika, Rajat Sarin, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239HR2019PTC083569
- Company No.
083569
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Nov 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Micropolis Lifesciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajat Sarin  | Director | 14-Nov-2019 | Current |
| Jatinder Sharda | Additional Director | Current | |
| Mandeepika | Director | 14-Nov-2019 | Current |
| Sonia Rani | Additional Director | Current |
Financial Performance and Corporate Structure Insights of Micropolis Lifesciences.
Micropolis Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 63.47% increase. The company also saw a substantial improvement in profitability, with a 80.58% increase in profit. The company's net worth Soared by an impressive increase of 167.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Micropolis Lifesciences?
In 2023, Micropolis Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aclivia Healthcare Private Limited
Active
1 year 10 months Jatinder Sharda and Rajat Sarin are mutual person
Ultrapolis Lifesciences Private Limited
Active 1 year 10 months Jatinder Sharda and Mandeepika are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 May 2023 | ₹1.30 Cr | Open |
Others Creation Date: 11 Oct 2022 | ₹1.22 M | Open |
How Many Employees Work at Micropolis Lifesciences?
Unlock and access historical data on people associated with Micropolis Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Micropolis Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Micropolis Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
